Wednesday, December 19, 2018
Sanofi Launches 'Once Daily' Oral, Teriflunomide 14 mg Tablet 'Aubagio®'- for Treatment of Multiple Sclerosis in India
  SocialTwist Tell-a-Friend  

MUMBAI, December 5, 2018 /PRNewswire/ --

- Aubagio ® (Teriflunomide, 14 mg) offers patients diagnosed with Multiple Sclerosis the efficacy and convenience of once-a-day oral treatment

- Over 200,000 people in India are living with Multiple Sclerosis[1]

Sanofi Genzyme, the specialty care global business unit of Sanofi, brings to India - Aubagio ® (Teriflunomide, 14 mg), from its international Multiple Sclerosis (MS) portfolio. Multiple Sclerosis is a chronic debilitating disease of the nervous system with varied symptoms like weakness in the limbs, poor vision, fatigue or slurred speech.

        (Logo: )

        (Photo: )

Aubagio ® (Teriflunomide, 14 mg) is the first original 'once-daily' oral 'disease modifying therapy' (DMT) for Multiple Sclerosis to be approved in India. It offers an effective, safe and a convenient option that is indicated as a first-line treatment for relapsing forms of Multiple Sclerosis that must be taken once a day, with or without food.

Commenting on the launch, N. Rajaram, Managing Director, Sanofi India, said, "There are around two lakh people living with this disease in India. There are increasing numbers of cases being detected due to greater awareness and access to better diagnostic facilities. Millions of patients depend on us for their healthcare needs, and as a health journey partner, we understand the many challenges that people with Multiple Sclerosis face."  

He added, "For over a decade Sanofi has invested in developing and delivering novel therapeutic solutions for treatment of Multiple Sclerosis around the world; and with that, we have now brought our original research product to India. This product has the potential to offer an efficacious and convenient treatment regimen of just once a day oral tablet, vis-Ă -vis common treatment options that are injectables. With Aubagio ® (Teriflunomide, 14 mg), we reiterate Sanofi Genzyme's commitment to improve and empower the lives of people with debilitating diseases in India."

Dr. Shalini Menon, Head - Medical Affairs, India & South Asia, Sanofi, said, "Aubagio ® (Teriflunomide, 14 mg) is a differentiated disease modifying therapy, that blocks the enzyme involved in multiplication of overactive immune cells. When taken daily, Aubagio ® (Teriflunomide, 14 mg) reduces the number of overactive immune cells that cause the disease flare-ups, while still allowing normal immune cell activity to occur. It is important to note that Aubagio ® (Teriflunomide, 14 mg) has demonstrated consistent efficacy in reducing the frequency of relapses, delaying the accumulation of physical disability and, arresting further decrease in brain volume. In addition, given its convenience as an oral medicine, Aubagio ® (Teriflunomide, 14 mg) encourages people with Multiple Sclerosis to continue with long-term treatment."

First approved by the US FDA in 2012, Aubagio ®  (Teriflunomide, 14 mg) has a strong global presence today with approvals in more than 81 countries.[3] It has been extensively studied in more than 5,500 patients with up to 13 years of clinical and follow-up studies with proven clinical efficacy, safety and tolerability outcomes.[3] Globally, more than 85,000 patients with Multiple Sclerosis are benefitting from the use of Aubagio ® [3].

About Multiple Sclerosis:  

Multiple Sclerosis is an autoimmune, debilitating disease of the nervous system that affects the spinal cord and brain. In Multiple Sclerosis, there is progressive damage to the sheath that protects nerve cells, impairing communication between the brain and the nervous system. Signs and symptoms vary from one person to another and may include: weakness and numbness in the limbs, poor vision, tingling and pain in parts of the body, unsteady gait, lack of coordination, fatigue or slurred speech. Most people develop a 'relapsing-remitting' form of Multiple Sclerosis where symptoms ('relapses') may last for days or weeks and then improve completely or partially. This is then followed by a period of remission that could last for months or even years.[2]Multiple Sclerosis is a common cause of disability that usually affects young persons during their most productive years but only 45% of all patients are correctly diagnosed.[4] Research shows across the world, over 2.3 million people are living with Multiple Sclerosis.[5]

About Aubagio ® (Teriflunomide, 14 mg)  

Aubagio ® (Teriflunomide, 14 mg) is an innovator product with almost 13 years of proven clinical efficacy, safety and tolerability data, and is a best in class medication for relapsing and remitting Multiple Sclerosis. It is a differentiated Disease-Modifying Therapy (DMT), which works by blocking the enzyme needed for immune cells to keep multiplying at an overactive rate. When taken daily, Aubagio ® reduces the number of overactive immune cells [that causes the disease flare-ups, while still allowing normal immune cell activity to occur]. Unlike other medicines, Aubagio ® is India's first innovator 'once-daily' oral pill to treat Multiple Sclerosis in India. It can be taken any time of the day, with or without food. This ensures patient adherence and convenience, both of which are missing in currently available Multiple Sclerosis therapies.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi Genzyme, the specialty care global business unit of Sanofi, is focused on rare diseases, multiple sclerosis, and immunology. It focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Sanofi Genzyme is recognized as one of the industry's most generous in-kind givers and 2018 marks the 20th year of Sanofi Genzyme’s charitable access program in India. Through this program, known as INCAP (INdia Charitable Access Program), Sanofi Genzyme is currently providing free Enzyme Replacement Therapy to patients with Lysosomal Storage Disorders (LSDs) in India.

[1] Accessed on July 4, 2018  (This was in the context of - Currently, in almost 90% cases , Multiple Sclerosis treatment is driven by injectables)

[2] Mayo Clinic. Multiple Sclerosis. Available at: Accessed on May 24, 2018.

[3] Genzyme data on File

[4] Genzyme data on File (As per market research done in 2015)


Media Contact:
Sohil Bahamania
Communications, Sanofi

More News by PR Newswire India

Bentall Kennedy and GreenOak Real Estate announce merger to form Bentall GreenOak, global real estate investment platform

Mumbai Jewellery & Gem Fair to Showcase Statement Pieces From Prime Indian Jewellers

Essence takes on integrated media duties for Airtel

JA Solar Supplies Modules for the First 3MW Bifacial Mono PERC Double Glass Solar Project in Brazil

Metasys(R) 10.0 redefines modern building management

Lipofilling, Expanded Stem Cells Are a Valuable Alternative to Breast Implants

Locus Chain to Launch a Digital Asset Exchange Platform in Dubai

Wood Adhesives Manufacturers Focus their Growth Strategy on Furniture, Building and Construction Industries

The Commonwealth Of The Bahamas New Visa Waiver Policy for Indian Nationals Holding Canadian, Schengen, USA and UK Visas

Big Data and IoT Advancements Drive Growth Opportunities for Prognostics in Commercial Vehicles

Supermicro Report Highlights Environmental Impact of Today's Cloud-Scale Data Centers

HTC Partners With China Mobile To Expand Its 5G Vision Globally

HUAWEI P20 Pro Honoured at the Prestigious News18 Tech and Auto Awards for Best Camera Phone of the Year

Intermarché maps its own-brand organic products using SGS Transparency-One

Xevo Recognized by Frost & Sullivan for its Groundbreaking Xevo Market Automotive Commerce and Services Platform

TATA Projects Builds Prayagraj Airport Terminal in 11 Months

New Report Explores Digital Travel Commerce and Payments Needs in Latin America & Caribbean

ThroughPut Inc Announces the Formation of Executive Advisory Board, Welcomes New Members

27th Mega Eye Camp Held at Dera Sacha Sauda

Mumbai to get its First Professionally Managed Self-redevelopment Project by Wedevelopment

ARLANXEO's Keltan(R) KSA opens flagship online Customer Self-Service Platform

Western Digital Hosts 'Data Innovation Bazaar' in Association With 'Startup India' and 'Invest India'

GIIS Chinchwad Amongst 0.1% Schools in India to Receive Cambridge Affiliation

Munters Wins Three Large Air Treatment Orders in China

Datamatics Recognized as the Best Cognitive Technology Provider by Computer Society of India, Mumbai

Indiannica Learning Organizes English Language Training (ELT) Workshop and Product Launch

Nishchae Suri to Join the Global Management Executive Team at EdCast

'Marketing Success Formula' a New Book by Rajesh Srinivasan (an IIM-L Alumnus) Reveals Four Proven Steps for Business Growth

HopOn India to Participate in Comic-Con 2018

Lenovo and Intel's Much-anticipated Legion of Champions III 2019 is Here and Raring to Go

UST Global Awarded 'Top Employers in the APAC for 2019' by the Top Employers Institute

Singapore Post eCommerce Division Recognised at the 2018 Asia eCommerce Awards

Empire State Building And Interscope Records, Along With iHeartMedia, Promise A "White Christmas" With Annual Holiday Music-To-Light Show Featuring OneRepublic

Shoclef Presents Live Shopping in the Global Marketplace

Ski Season Opens at Lotte Arai Resort on December 15

AWE 2019 releases new theme: Falling in love with AI - Smart Life

New Report Shows Rapid Damage to Milk Nutrients by Light

Artificial Intelligence Is Propelling the Pharmaceutical Industry by Enabling Smart Drug Discovery Solutions

Few Months Into the Launch, NowPaaS is Already a Success; Has Serviced More Than 100+ Manufacturers

Cityzenith's Smart World Pro™ Digital Twin Software Platform Selected for New Capital City in India

Frost & Sullivan Applauds VMware for Global Software-Defined Wide Area Networking (SD-WAN) Market Leadership

The Rise of Industrial IoT Drives the Adoption of Predictive Inspection Models in Non-destructive Testing

After New Delhi, Indus Towers now Deploys 50 Intelligent Poles in Vadodara Under Government's Smart City Mission

Systech Releases Expanded Cloud Platform to Secure Global Supply Chains

KC Valley: MEIL’s another Glory

Top IT Jobs in Demand in India, Revealed by Simplilearn Study

Maxim India Achieves the Distinction of India's First Progressive 3D Mainstream Magazine Cover - Courtesy OnePlus

Microland Wins Best Practice Award at the NHRD TecHeaRt 2018

Kerala Tourism Launches International Children's Online Painting Competition 2018 in Memory of Edmund Thomas Clint

Fosun's Protechting Program wins UNGC's China Network award for its Sustainable Development in China

Cross-border Data Flows Fundamental for AI Growth in India

Affle Wins Big at MOBEXX Awards 2018

BioNet reports on persistence of antibody responses of recombinant pertussis vaccines in the Lancet Infectious Diseases

Datamatics to Demerge and Separately List its Subsidiary Lumina Datamatics

Dunya Labs Brings EOS Blockchain to India With Catalyst

Exclusive Launch: Karan Wahi X Spoyl Collection

Join in the 2018 world-leading Tea Fair with the gracious invitation extended by Huajuchen

Cold Delhi morning with very poor air...
India retains highest aviation safety ra...
Rahul takes tuition to dream, what to sp...
Vyapam scam: CBI court sentences 1 accus...
BJP MP son sent to jail in SC/ST Act...
Odisha BJP chief demands loan waiver for...
 Top Stories
Shuttlecock makers in Bengal's Ulub... 
I got my first negative review afte... 
BJP showing Parrikar as 'He-man, Su... 
Sonu Nigam clarifies his comment on... 
Most firms bet big on 5G but wary o... 
AgustaWestland case: CBI opposes Ch... 
Unaware of 2020 Sikh referendum cam... 
Cricket Ireland to offer profession...